Physician profile
Stephen L Harless
NPI 1336151976
$3,912.67
in general payments reported to CMS, 2019-2025
33 companies · $679 in 2025
The $679 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $250 · 2021: $325 · 2022: $575 · 2023: $657 · 2024: $714 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $907.71 | 2019-2025 | |
| Novo Nordisk INC | $406.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $329.82 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $272.19 | 2019-2024 | Belsomra, Verquvo, Steglatro |
| Abbvie INC. | $211.52 | 2021-2025 | |
| Glaxosmithkline, LLC. | $193.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $185.18 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $164.43 | 2019-2024 | |
| Lilly USA, LLC | $107.89 | 2022-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $89.54 | 2022-2025 | Livalo, Zoryve, Seglentis |
| Astellas Pharma US INC | $82.19 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.70 | 2019-2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $77.26 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $70.38 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $70.15 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $67.41 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $63.30 | 2019-2022 | |
| Lundbeck LLC | $63.01 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $55.06 | 2024 | Voquezna |
| Exact Sciences Corporation | $52.29 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $48.39 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.76 | 2019-2023 | Jardiance |
| Paratek Pharmaceuticals, INC. | $43.39 | 2024-2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $40.22 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.28 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.80 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $17.61 | 2022 | |
| Shield Therapeutics INC | $17.50 | 2023 | Accrufer |
| Esperion Therapeutics, INC. | $17.14 | 2025 | Nexletol |
| Mission Pharmacal Company | $16.60 | 2019 | |
| Mylan Specialty L.P. | $14.80 | 2019 | |
| Capsovision, INC. | $14.67 | 2025 | Capsocam Plus |
| Biohaven Pharmaceutical Holding Company LTD. | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Harless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.